Biomarkers for liver cancer using N-Glycan MALDI Imaging

MALDI Imaging is a powerful tool that can not only provide stunning visuals of tissues but also serve as an important tool in answering biological questions.

Join Dr. Anand Mehta from the Medical University of South Carolina as he gives an overview of his work with imaging N-linked glycans from liver cancer tissues. He will share how this technology is being used to advance clinical research in disease prognosis, biomarker evaluation, and druggable targets.

This LabCast will also give you a front-row seat to see our experts demonstrate these techniques, so you can practice them in your own lab. There will also be an opportunity to ask questions at the end.

This LabCast demonstrates:

• The principles of MALDI Imaging and how it is used to analyze N-linked glycans

• Sample preparation and data acquisition techniques

• Multiomic and multimodal data analysis strategies

Who should attend:

• Researchers interested in learning how to use MALDI Imaging to study N-linked glycans in tissues

• Anyone who is interested in learning more about MALDI Imaging and its applications in clinical research

• No prior experience with MALDI Imaging is required.

Presenter: Anand Mehta (DPhil, Professor, Endowed SmartState Chair in Proteomic Biomarkers, Medical University of South Carolina, Charleston, South Carolina, USA)

Dr. Anand Mehta is a Professor at the Medical University of South Carolina, where his research work focuses on the glycobiology of liver cancer and the identification and development of glycan-based biomarkers for the early detection of cancer. Together with Dr. Rick Drake and Dr. Peggi Angel at MUSC, Dr. Mehta has pioneered the utilization of MALDI Imaging for the analysis of N-linked glycans utilizing multiple N-glycan-targeting enzymes including PNGase F. To date, Dr. Mehta has authored over 100 research articles on topics including the glycobiology of liver cancer and the identification of cancer biomarkers. Dr. Mehta has also been awarded multiple U.S. patents on liver pathology and glycan-based biomarkers of liver cancer. Dr. Mehta’s current work focuses on the development of high-throughput MALDI Imaging-based platforms for the identification and validation of cancer biomarkers in both tissue and serum samples.

Presenter: Andrew DelaCourt (Ph.D., Field Application Scientist in Imaging, Bruker, Charleston, South Carolina, USA)

Dr. Andrew DelaCourt is a Field Application Scientist at Bruker focusing on MALDI Imaging applications. Dr. DelaCourt recently completed his Ph.D. work in the laboratory of Dr. Anand Mehta at the Medical University of South Carolina, where he utilized MALDI Imaging for the identification of N-linked glycan biomarkers of genetic subtypes of hepatocellular carcinoma. Dr. DelaCourt brings his expertise in cancer biology and glycobiology to Bruker in order to further contribute to the application of MALDI Imaging in those areas.

Presenter: Daniel Castro (Ph.D., Application Scientist in Imaging, Bruker, Billerica, Massachusetts, USA)

Dr. Daniel Castro is an Application Scientist at Bruker focusing on MALDI Imaging. Dr. Castro completed his Ph.D. in the lab of Jonathan Sweedler at the University of Illinois-Urbana-Champaign, where he focused on high-throughput single-cell and single-organelle measurements as well as accelerating tissue MALDI-FTICR imaging. Dr. Castro, is an expert in high-throughput MALDI measurements.